Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of JNJ-95475939 vs dupilumab and placebo in moderate to severe atopic dermatitis
jRCT2031240728Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of JNJ-95475939 in atopic dermatitis (AD) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: EASI-75 response at Week 12. Started Apr 2025; status: completed.
02
Drugs
JNJ-95475939
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031240728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240728.